RCUS•benzinga•
B of A Securities Maintains Neutral on Arcus Biosciences, Lowers Price Target to $17
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 19, 2025 by benzinga